A Phase 1 interventional study of TAK-438 in Healthy Participants, sponsored by Takeda. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-30.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the pharmacokinetics (PK) of TAK-438 in healthy adult Chinese participants after both single and multiple dose administration.
The drug being tested in this study is called TAK-438. TAK-438 is being tested in healthy participants in order to evaluate the PK of single and multiple oral dose.
The study will enroll approximately 36 healthy participants. Participants will be assigned to one of the three treatment groups:
This single-centre trial will be conducted in China. The overall time to participate in this study is 18 days. Participants will remain confined to the clinic from Day 1 up to Day 11 and will be followed-up by telephone or visit on Day 18.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-438 10 mg, tablets, orally, once daily on Days 1, 3-9. Participants were required to fast for a minimum of 10 hours prior administration of assigned treatment.
Drug: TAK-438
TAK-438 20 mg, tablets, orally, once daily on Days 1, 3-9. Participants were asked to fast for a minimum of 10 hours prior administration of assigned treatment.
Drug: TAK-438
TAK-438 20 mg, tablets, orally, once on Day 1 and twice daily on Days 3-9. Participants were asked to fast for a minimum of 10 hours prior to breakfast, followed by administration of assigned treatment 0.5 hours after breakfast and dinner.
Drug: TAK-438
TAK-438 tablets.
Cmax: Maximum Observed Plasma Concentration for Free Base of TAK-438 (TAK-438F) and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Tau Over the Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
T1/2z: Terminal Disposition Half-life for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Cmax,ss: Maximum Observed Plasma Concentration, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Tmax, ss: Time to Reach the Maximum Plasma Concentration (Cmax) at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
AUCτ,ss: Area Under the Plasma Concentration-time Curve During a Dosing Interval, at Steady State for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Aet: Total Amount of Drug Excreted in Urine From Time 0 to Time T for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Fe,t: Fraction of Drug Excreted in Urine From Time 0 to Time t for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
CLr: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 1
Time frame: Day 1 pre-dose and at multiple timepoints (up to 48 hours) post-dose
Aeτ: Amount of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Fe,τ: Fraction of Administered Dose of Drug Excreted in Urine During a Dosing Interval for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
CLR: Renal Clearance for TAK-438F and Its Metabolites M-I, M-II, M-III and M-IV-Sul on Day 9
Time frame: Day 9 pre-dose and at multiple timepoints (up to 24 hours for TAK-483 10 mg once daily and 20 mg once daily; up to 12 hours for TAK-438 20 mg twice daily) post-dose
Participants took part in the study at 1 investigative site in China from 19 April 2017 to 17 August 2017.
| Milestone | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| Started | 12 | 11 | 10 |
| Completed | 12 | 11 | 10 |
| Not completed | 0 | 0 | 0 |
| nanogram per milliliter (ng/mL) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 9.148 ± 2.9972 | 18.18 ± 4.4973 | 25.23 ± 10.017 |
| M-I | 38.32 ± 8.6143 | 67.95 ± 23.388 | 59.02 ± 18.443 |
| M-II | 2.840 ± 1.0442 | 5.155 ± 2.7868 | 4.879 ± 2.2426 |
| M-III | 15.42 ± 3.7788 | 25.63 ± 7.8650 | 25.67 ± 5.9219 |
| M-IV-Sul | 28.29 ± 5.0563 | 60.67 ± 16.499 | 42.28 ± 9.1174 |
| hour | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 1.750 (1.00 to 4.02) | 2.000 (0.750 to 4.00) | 2.500 (0.750 to 4.00) |
| M-I | 1.500 (0.750 to 2.00) | 1.500 (0.750 to 3.00) | 2.000 (1.00 to 4.00) |
| M-II | 4.010 (3.00 to 10.0) | 6.000 (3.00 to 10.0) | 10.00 (3.00 to 12.0) |
| M-III | 1.750 (1.00 to 2.00) | 2.000 (1.50 to 3.00) | 2.000 (1.50 to 4.00) |
| M-IV-Sul | 1.500 (1.00 to 2.00) | 1.500 (1.50 to 3.00) | 2.000 (1.50 to 3.00) |
| hour*nanogram per milliliter (h*ng/mL) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 84.38 ± 29.197 | 188.1 ± 43.066 | 226.8 ± 67.128 |
| M-I | 305.7 ± 88.227 | 617.2 ± 213.56 | 578.7 ± 144.15 |
| M-II | 52.97 ± 22.843 | 106.3 ± 74.306 | 117.8 ± 41.170 |
| M-III | 92.83 ± 34.769 | 178.7 ± 64.779 | 193.7 ± 56.808 |
| M-IV-Sul | 132.5 ± 44.602 | 307.5 ± 89.884 | 240.8 ± 82.555 |
| h*ng/mL | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 74.91 ± 24.835 | 168.6 ± 37.455 | 154.8 ± 38.920 |
| M-I | 251.4 ± 77.758 | 528.8 ± 182.62 | 344.1 ± 91.089 |
| M-II | 31.77 ± 18.646 | 79.07 ± 56.206 | 41.55 ± 19.189 |
| M-III | 87.98 ± 31.136 | 169.2 ± 59.474 | 149.1 ± 36.714 |
| M-IV-Sul | 127.1 ± 43.648 | 296.0 ± 86.359 | 192.8 ± 57.176 |
| hour | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 7.879 ± 1.2352 | 6.996 ± 1.0110 | 7.116 ± 0.71638 |
| M-I | 10.82 ± 4.0923 | 8.256 ± 1.2964 | 8.385 ± 0.73316 |
| M-II | 10.52 ± 4.3311 | 10.37 ± 2.9973 | 12.29 ± 4.0538 |
| M-III | 6.695 ± 1.3786 | 6.335 ± 1.1833 | 6.791 ± 0.89228 |
| M-IV-Sul | 4.753 ± 2.4430 | 5.698 ± 1.2625 | 5.521 ± 2.2225 |
| ng/mL | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 11.01 ± 3.4863 | 23.43 ± 6.1433 | 37.88 ± 10.910 |
| M-I | 43.39 ± 9.6528 | 79.85 ± 22.119 | 59.55 ± 15.512 |
| M-II | 3.558 ± 1.4983 | 6.554 ± 2.6078 | 9.174 ± 2.8376 |
| M-III | 16.62 ± 4.1919 | 30.15 ± 7.3228 | 33.01 ± 6.1638 |
| M-IV-Sul | 25.33 ± 3.6619 | 54.08 ± 13.927 | 39.74 ± 7.1405 |
| hour | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 1.500 (0.750 to 3.02) | 2.000 (0.750 to 3.00) | 3.000 (0.750 to 4.00) |
| M-I | 1.500 (0.750 to 2.02) | 1.000 (0.750 to 2.00) | 2.500 (1.00 to 10.0) |
| M-II | 4.000 (3.00 to 6.00) | 3.000 (3.00 to 10.0) | 3.500 (0.00 to 10.0) |
| M-III | 1.750 (1.00 to 3.00) | 2.000 (1.50 to 3.00) | 3.000 (1.50 to 4.00) |
| M-IV-Sul | 2.000 (1.00 to 3.00) | 1.500 (1.50 to 2.00) | 3.000 (1.50 to 4.00) |
| h*ng/mL | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 93.90 ± 28.053 | 212.7 ± 57.214 | 273.4 ± 71.830 |
| M-I | 285.5 ± 77.884 | 581.1 ± 198.14 | 435.3 ± 92.064 |
| M-II | 46.31 ± 24.298 | 105.5 ± 51.688 | 100.4 ± 27.966 |
| M-III | 95.94 ± 29.719 | 194.6 ± 53.749 | 222.6 ± 49.670 |
| M-IV-Sul | 117.1 ± 37.489 | 256.1 ± 62.786 | 225.7 ± 52.675 |
| microgram (mcg) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 448.5 ± 159.06 | 890.3 ± 243.24 | 1478 ± 405.32 |
| M-I | 176.6 ± 79.813 | 253.1 ± 118.69 | 211.2 ± 124.21 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.5120 ± 1.6191 |
| M-IV-Sul | 205.4 ± 61.587 | 422.1 ± 143.24 | 387.1 ± 142.06 |
| percentage of drug | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 4.485 ± 1.5906 | 4.448 ± 1.2093 | 7.399 ± 2.0335 |
| M-I | 1.760 ± 0.79678 | 1.262 ± 0.59122 | 1.053 ± 0.61992 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.002460 ± 0.0077792 |
| M-IV-Sul | 1.609 ± 0.48258 | 1.650 ± 0.56108 | 1.513 ± 0.55536 |
| liter per hour (L/h) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 5.443 ± 1.0398 | 4.922 ± 1.4362 | 6.733 ± 1.3109 |
| M-I | 0.6235 ± 0.16437 | 0.4465 ± 0.24193 | 0.3753 ± 0.19679 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.001820 ± 0.0057553 |
| M-IV-Sul | 1.748 ± 0.65948 | 1.527 ± 0.77444 | 1.707 ± 0.47416 |
| mcg | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 437.7 ± 121.93 | 859.9 ± 155.66 | 1327 ± 274.04 |
| M-I | 224.3 ± 79.531 | 354.1 ± 165.88 | 340.9 ± 181.71 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-IV-Sul | 205.2 ± 52.172 | 390.7 ± 99.477 | 446.4 ± 139.39 |
| percentage of drug | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 4.377 ± 1.2193 | 4.299 ± 0.77678 | 6.634 ± 1.3737 |
| M-I | 2.236 ± 0.79323 | 1.765 ± 0.82755 | 1.700 ± 0.90664 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-IV-Sul | 1.605 ± 0.40853 | 1.528 ± 0.38946 | 1.748 ± 0.54499 |
| L/h | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| TAK-438F | 4.848 ± 1.2372 | 4.251 ± 1.1565 | 4.977 ± 0.71952 |
| M-I | 0.8126 ± 0.26393 | 0.6207 ± 0.22632 | 0.7943 ± 0.39001 |
| M-II | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-III | 0.000 ± 0.0000 | 0.000 ± 0.0000 | 0.000 ± 0.0000 |
| M-IV-Sul | 1.931 ± 0.79907 | 1.614 ± 0.58643 | 2.067 ± 0.70761 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to follow-up (Day 1 up to Day 18). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAK-438 10 mg Once Daily | 0/12 (0%) | 0/12 (0%) | 4/12 (33.3%) |
| TAK-438 20 mg Once Daily | 0/11 (0%) | 0/11 (0%) | 6/11 (54.5%) |
| TAK-438 20 mg Twice Daily | 0/10 (0%) | 0/10 (0%) | 4/10 (40%) |
| Event | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily |
|---|---|---|---|
| White blood cells urine positiveInvestigations | 1/12 | 2/11 | 2/10 |
| Red blood cells urine positiveInvestigations | 2/12 | 0/11 | 2/10 |
| Abdominal pain upperGastrointestinal disorders | 0/12 | 1/11 | 1/10 |
| Alanine aminotransferase increasedInvestigations | 0/12 | 0/11 | 1/10 |
| Aspartate aminotransferase increasedInvestigations | 0/12 | 0/11 | 1/10 |
| Blood creatine phosphokinase increasedInvestigations | 0/12 | 0/11 | 1/10 |
| Glucose urine presentInvestigations | 0/12 | 0/11 | 1/10 |
| Protein urine presentInvestigations | 0/12 | 0/11 | 1/10 |
| Atrioventricular block first degreeCardiac disorders | 0/12 | 1/11 | 0/10 |
| Urinary tract infectionInfections and infestations | 0/12 | 1/11 | 0/10 |
The pharmacokinetic (PK) set included all participants who received the study drug, had sufficient plasma/urine concentration data to calculate at least 1 PK parameter, and completed the minimum protocol specified procedures with no significant protocol deviations.
| Age, Continuous(years) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Mean | 25.2 ± 2.95 | 23.9 ± 3.99 | 27.2 ± 4.83 | 25.4 ± 4.04 |
| Sex: Female, Male(Participants) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Female | 6 | 5 | 4 | 15 |
| Male | 6 | 6 | 6 | 18 |
| Race (NIH/OMB)(Participants) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 12 | 11 | 10 | 33 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| China | 12 | 11 | 10 | 33 |
| Height(centimeter (cm)) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Mean | 166.35 ± 8.426 | 169.59 ± 7.672 | 164.31 ± 9.377 | 166.81 ± 8.498 |
| Weight(kilogram (kg)) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Mean | 62.63 ± 7.601 | 66.05 ± 8.501 | 61.66 ± 6.449 | 63.47 ± 7.597 |
| Body mass index (BMI)(kilogram per square meter (kg/m^2)) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Mean | 22.63 ± 2.086 | 22.89 ± 1.711 | 22.88 ± 2.110 | 22.79 ± 1.918 |
| Smoking classification(Participants) | TAK-438 10 mg Once Daily | TAK-438 20 mg Once Daily | TAK-438 20 mg Twice Daily | Total |
|---|---|---|---|---|
| Never smoked | 12 | 11 | 10 | 33 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in Aug 2017, 3 months.
Results were first posted in Jan 2019, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vonoprazan